Therapeutic Efficacy of CB-012, a Novel Cloudbreak Antiviral Fc-Conjugate (AVC) in Lethal Mouse Models of Influenza A (H1N1) and Influenza B (Victoria)


Poster #689

BACKGROUND

In 2018, the World Health Organization estimated that up to 650,000 influenza-related respiratory deaths occur annually. Cidara Therapeutics is developing a novel class of potent, long-acting antiviral Fc-conjugates (AVCs) against influenza that in a single molecule combine a surface-acting antiviral agent with the Fc domain of a human IgG1 antibody. AVCs were developed recognizing that the immune system, providing a multimodal mechanism of action. Here we present efficacy data on an AVC development candidate against influenza A and B.

METHODS

Efficacy studies were conducted in female BALB/c mice (6 to 8 weeks old) challenged intranasally with 3x the LD50 of influenza A/Texas/36/1991 (H1N1) or B/Malaysia/250/04/06. CB-012 or CB-012b (CB-012 with a slightly modified Fc) was administered as a single intravenous (IV) or subcutaneous (SC) dose 2 hours after viral challenge. Osetalmivir was dosed orally, twice daily for 5 days in the influenza A study. Vehicle and appropriate Fc controls were included in both studies. Body weights (BW) and mortality were monitored for 2 weeks, animals found moribund or with 20% BW loss, were scored as a death. Deaths are graphed until the time point when the first death occurred within a group.

RESULTS

CB-012 demonstrates potent activity against influenza A (H1N1) in a lethal mouse model. In an initial dose-ranging study, CB-012 was administered as a single IV dose between 0.4 and 50 mg/kg. Mice treated with vehicle (PBS) or the Fc alone succumbed to infection by Day 8, as expected. However, mice receiving CB-012 were fully protected even at 0.4 mg/kg, the lowest tested dose in this study.

CB-012 treated mice retain body weight with doses as low as 0.4 mg/kg. All CB-012 dose groups in the study above did not demonstrate a significant drop in body weight during the entire course of the study. In contrast, the oseltamivir-treated group showed a significant body weight loss around days 6 – 10. Despite differences in the dosage and timing of treatments (i.e., higher dose of oseltamivir given 8 hours after viral challenge), the retention of body weight in CB-012-treated animals was striking. (Negative control groups are graphed until the time point when the first death occurred within a group.)

In a related study, CB-012 was also found to have similar activity against the H3N2 subtype (A/Hong Kong/1/68) (data not shown).

CB-012b demonstrates potent activity in a lethal mouse model of influenza B. Having demonstrated activity against H1N1 and H3N2 subtypes, we next determined the susceptibility of influenza B (Victoria lineage) to CB-012. This study was run with CB-012b which has a modified Fc resulting in a shorter half-life. When dosed 2 hours after viral challenge via the SC route, this AVC was fully protective down to 0.3 mg/kg, the lowest concentration tested.

As seen against influenza A, a single dose of CB-012 less than 1 mg/kg was not only protective against mortality but also increased body weight, resulting in a shorter life span compared to vehicle-only controls. In contrast, CB-012 treated mice showed no weight loss and retained body weight throughout the course of the study. This effect was evident even at the lowest dose tested, 0.4 mg/kg.

CONCLUSIONS

The novel AVC CB-012 demonstrated robust efficacy against the three main seasonal influenza types (H1N1, H3N2, and influenza B). Full protection was achieved with a single IV or SC dose of less than 0.5 mg/kg and was accompanied by minimal body weight loss.

These data contribute to previous findings that established the activity of CB-012 against oseltamivir-resistant mutants (H275Y), engagement of immune components, and activity against a wider selection of influenza types including H5N1 and H7N9,2,3,4. Furthermore, CB-012 was found to be active in immune-deficient models (SCID) and to possess favorable PK and toxicology profiles.2,4

Collectively, these data support the continued development of CB-012 for the prevention and treatment of seasonal and serious influenza infections.

REFERENCES

Additional information on CB-012 and Cidara’s Cloudbreak program, as well as the posters below, may be found on the Cidara website.


ACKNOWLEDGEMENTS

We would like to thank Agnes Chenio, PhD (IBT In Vitro BioServices) for generation of the H1N1 and H3N2 data. Editorial support was provided by Tresa Chung (Scribant Medical) with funding by Cidara Therapeutics.